Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$3.58M+2343.84%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven George Lydeamore
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Beta
- 0.51
- Country
- AU
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -5.66
Financials
Revenue
$3.58M+2343.8%Net Income
$-1.95MEBITDA
$-2.46MFree Cash Flow
$-767.4KEPS (diluted)
$-0.24Shares Outstanding (diluted)
8.13M+8468.1%Operating Expenses
$4.05MCash & Debt
$9.02MRevenue by Segment (annual)
$50.2KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $7.55M | $-3.75M | $-0.50 |
| 2025 | $7.29M | $-5.22M | $-0.90 |
| 2024 | $4.90M | $-6.94M | $-1.22 |
| 2023 | $1.80M | $-3.79M | $-0.66 |
| 2022 | $765.2K | $-2.85M | $-0.50 |
| 2021 | $145.8K | $-8.38M | $-1.52 |
| 2020 | $2.52M | $-2.93M | $-0.66 |
| 2019 | $2.39M | $-4.66M | $-1.29 |
| 2018 | $1.84M | $-3.01M | $-0.90 |
| 2017 | $1.40M | $-6.80M | $-2.57 |
| 2016 | $1.00M | $-7.07M | $-3.70 |
| 2015 | $1.00M | $-2.69M | $-1.44 |
| 2014 | $1.00M | $-2.69M | $-1.44 |
| 2013 | $149.8K | $-3.54M | $-13.60 |
Valuation
IMRNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·12d ago·Neutral
Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives MELBOURNE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in evaluation of strategic initiatives aimed at maximising shareholder value.
View source ↗ - Newsglobenewswire.com·26d ago·Positive
…n 19% on prior comparative period (pcp) Q1 sales down 24% on prior quarter MELBOURNE, Australia, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce double digit sales growth (unaudited) in the quarter ending September 30, 2026. Continued Travelan® Australian sales growth in Q1 FY27 (+14% on pcp) in Australia can be attributed to the new Travelan® brand re-launch, including new pa…
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerging Growth Conference on Wednesday 28th October 2026 (4:25pm – 4:55pm U.S. Eastern Time).
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Travelan® Phase 2 Study Results Published MELBOURNE, Australia, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that data from its Phase 2 clinical trial of once-daily oral Travelan® has been published in the Nature Journal, Scientific Reports. A copy of the publication can be accessed here: https://doi.org/10.1038/s41598-026-70974-9 The article titled, "A phase 2, randomized, placebo-controlled study to evaluate once-daily oral Travelan for the prevent…
View source ↗ - Newsglobenewswire.com·79d ago·Neutral
Immuron to launch PROIBS® in the United States MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. Immuron launched PROIBS® in Australia during FY26.
View source ↗
Earnings
Fri, Feb 19(in 3 months)
Consensus estimate $-0.00 per share
Typical surprise -945.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 27$-0.00 vs $-0.00miss
- Wed, Feb 25$-0.20 vs $-0.01miss
- Thu, Aug 28$-0.01 vs $-0.01beat
- Fri, Feb 28$-0.27 vs $-0.01miss
Estimates and results for IMRN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMRN officers and directors.
No open-market trades in the recent filings. All 21 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
21 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMRN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
